Sensus Healthcare (NASDAQ:SRTS) Lowered to "Strong Sell" Rating by Wall Street Zen

Key Points

• Wall Street Zen downgraded Sensus Healthcare (NASDAQ:SRTS) from “sell” to “strong sell,” even though the broader analyst consensus still stands at “Moderate Buy.”
• Recent Q1 2026 results were weak: the company reported an EPS loss of $(0.16) versus expectations for $(0.12), and revenue of about $3.39 million fell well short of the $5.32 million estimate.
• There are some potential positives ahead, including an amicable resolution of a commercial dispute with SkinCure Oncology and management’s plan to target full-year profitability in 2026 as new CPT codes take effect.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "sell" rating to a "strong sell" rating in a note issued to investors on Saturday.

Several other research firms also recently commented on SRTS. Weiss Ratings reiterated a "sell (d)" rating on shares of Sensus Healthcare in a research report on Tuesday, April 21st. Alliance Global Partners initiated coverage on Sensus Healthcare in a research report on Friday, March 6th. They set a "buy" rating and a $7.50 price objective for the company. Citigroup reaffirmed a "buy" rating on shares of Sensus Healthcare in a research note on Friday. Finally, Maxim Group decreased their target price on Sensus Healthcare from $8.00 to $6.00 and set a "buy" rating for the company in a research note on Tuesday, February 17th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $6.88.

Sensus Healthcare Stock Performance

SRTS opened at $3.08 on Friday. The business's fifty day moving average is $4.14 and its 200-day moving average is $4.16. The firm has a market cap of $50.70 million, a P/E ratio of -6.55 and a beta of 1.19. Sensus Healthcare has a 52-week low of $2.82 and a 52-week high of $5.92.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.04). The business had revenue of $3.39 million during the quarter, compared to analyst estimates of $5.32 million. Sensus Healthcare had a negative net margin of 34.50% and a negative return on equity of 15.41%.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Opes Wealth Management LLC purchased a new position in shares of Sensus Healthcare during the third quarter valued at approximately $50,000. XTX Topco Ltd purchased a new position in shares of Sensus Healthcare during the fourth quarter valued at approximately $77,000. Jane Street Group LLC purchased a new position in shares of Sensus Healthcare during the fourth quarter valued at approximately $79,000. Mindset Wealth Management LLC boosted its position in shares of Sensus Healthcare by 28.1% during the third quarter. Mindset Wealth Management LLC now owns 50,100 shares of the company's stock valued at $157,000 after buying an additional 11,000 shares during the last quarter. Finally, Ingalls & Snyder LLC purchased a new position in shares of Sensus Healthcare during the fourth quarter valued at approximately $219,000. Hedge funds and other institutional investors own 25.30% of the company's stock.

Key Sensus Healthcare News

Here are the key news stories impacting Sensus Healthcare this week:

• Positive Sentiment: Sensus said it has amicably resolved its commercial dispute with SkinCure Oncology, which could reduce legal uncertainty and support a more stable operating outlook. Sensus Healthcare Announces Amicable Resolution of Commercial Dispute with SkinCure Oncology
• Positive Sentiment: Management outlined a full-year profitability goal for 2026, saying new CPT codes are now taking effect and could improve reimbursement and demand trends. Sensus outlines full year profitability goal for 2026 as new CPT codes take effect
• Neutral Sentiment: Recent earnings-call coverage focused on management’s recovery narrative and operational commentary, but did not add materially new financial information beyond the quarter’s results. Sensus Healthcare Charts Recovery Path Amid Revenue Drop
• Negative Sentiment: First-quarter 2026 results showed revenue of about $3.4 million, well below the prior year’s $8.3 million, while EPS of $(0.16) missed estimates and margins remained negative, reinforcing concerns about the company’s near-term growth and profitability. Sensus Healthcare Reports First Quarter 2026 Financial Results and Business Highlights

About Sensus Healthcare

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company's SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare's systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company's flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.